The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Cerubidin 20 mg Powder for Concentrate for Solution for Infusion

20 milligram(s) Pdr/Conc/Soln for Infus

Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/096/001

Main Information

Trade NameCerubidin 20 mg Powder for Concentrate for Solution for Infusion
Active SubstancesDaunorubicin hydrochloride
Strength20 milligram(s)
Dosage FormPdr/Conc/Soln for Infus
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/096/001

Group Information

ATC CodeL01DB Anthracyclines and related substances
L01DB02 daunorubicin


Licence Issued20/04/1995
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back